Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis
Sponsor: U.S. Army Medical Research and Development Command
This PHASE1/PHASE2 trial investigates Leishmaniasis and is currently completed. U.S. Army Medical Research and Development Command leads this study, which shows 12 recorded versions since 2004 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Aug 2019 — Feb 2020 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jun 2017 — Mar 2018 [monthly]
Completed PHASE1_PHASE2
Status: Enrolling By Invitation → Completed
-
Feb 2017 — Jun 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- U.S. Army Medical Research and Development Command
- Walter Reed Army Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .